Learn about the successful adult allogeneic bone marrow transplant performed at Zulekha Yenepoya Institute of Oncology. Find out how a 40-year-old man with relapsed acute myeloid leukaemia underwent a haploidentical transplant and recovered with minimal complications.
Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8% of Poseida and to receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy product candidate for solid tumors Astellas will have the right to designate an obser.
NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company.